The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
Simon Mallal - One of the best experts on this subject based on the ideXlab platform.
-
prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the western australian hiv cohort study
Clinical Infectious Diseases, 2006Co-Authors: Andri Rauch, David Nolan, E Mckinnon, C. Almeida, A. Martin, Simon MallalAbstract:Abacavir therapy is associated with significant drug hypersensitivity in ∼8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allelle. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701–negative recipients.
-
prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the western australian hiv cohort study
Clinical Infectious Diseases, 2006Co-Authors: Andri Rauch, David Nolan, E Mckinnon, C. Almeida, A. Martin, Simon MallalAbstract:Abacavir therapy is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allele. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701-negative recipients.
Mineo Kurokawa - One of the best experts on this subject based on the ideXlab platform.
-
Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors
Bone marrow transplantation, 2020Co-Authors: Satoko Morishima, Takahiro Fukuda, Noriko Doki, Takehiko Mori, Makoto Onizuka, Toshihiro Kawakita, Chiaki Kato, Yukiyasu Ozawa, Masatsugu Tanaka, Mineo KurokawaAbstract:In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the effects of patient and donor human leukocyte antigen (HLA) matching status on graft-versus-host disease (GVHD) have been extensively elucidated, but the effects of specific HLAs on acute GVHD remain unclear. Using data from a Japanese registry, we retrospectively analyzed 4392 patients with leukemia or myelodysplastic syndrome who received transplants from HLA-identical sibling donors to investigate the effects of HLAs on acute GVHD. From unbiased searches of HLA-A, -B, and -DR, HLA-B60 was significantly associated with an increased risk of grades II-IV acute GVHD (HR, 1.34; 95% CI, 1.13-1.59; P = 0.001). In contrast, HLA-B62 was significantly associated with a decreased risk of grades II-IV (HR, 0.73; 95% CI, 0.62-0.87; P < 0.001) and III-IV acute GVHD (HR, 0.63; 95% CI, 0.46-0.87; P = 0.005). The risk of leukemia relapse was significantly higher in HLA-B62-positive patients than in HLA-B62-negative patients (HR, 1.23; 95% CI, 1.05-1.43; P = 0.01). Both HLA-B60 and -B62 did not affect overall survival. The findings of this study may by implication suggest the possibility that the effects of specific HLAs on transplant outcomes may reflect inherent biological features, and thus consideration of specific HLAs may be helpful to predict transplant outcomes.
-
Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors
Bone Marrow Transplantation, 2020Co-Authors: Satoko Morishima, Takahiro Fukuda, Noriko Doki, Takehiko Mori, Makoto Onizuka, Toshihiro Kawakita, Chiaki Kato, Yukiyasu Ozawa, Masatsugu Tanaka, Mineo KurokawaAbstract:In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the effects of patient and donor human leukocyte antigen (HLA) matching status on graft-versus-host disease (GVHD) have been extensively elucidated, but the effects of specific HLAs on acute GVHD remain unclear. Using data from a Japanese registry, we retrospectively analyzed 4392 patients with leukemia or myelodysplastic syndrome who received transplants from HLA-identical sibling donors to investigate the effects of HLAs on acute GVHD. From unbiased searches of HLA-A, -B, and -DR, HLA-B60 was significantly associated with an increased risk of grades II–IV acute GVHD (HR, 1.34; 95% CI, 1.13–1.59; P = 0.001). In contrast, HLA-B62 was significantly associated with a decreased risk of grades II–IV (HR, 0.73; 95% CI, 0.62–0.87; P
Seigo Abiru - One of the best experts on this subject based on the ideXlab platform.
-
Association between Anti-Ganglionic Nicotinic Acetylcholine Receptor (gAChR) Antibodies and HLA-DRB1 Alleles in the Japanese Population
PLOS ONE, 2016Co-Authors: Yasuhiro Maeda, Osamu Higuchi, Akihiro Mukaino, Kiyoshi Migita, Hiroshi Furukawa, Atsumasa Komori, Minoru Nakamura, Satoru Hashimoto, Shinya Nagaoka, Seigo AbiruAbstract:Background/Aims Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibodies are observed in autoimmune diseases, as well as in patients with autoimmune autonomic ganglionopathy. However, the genetic background of anti-gAChR antibodies is unclear. Here, we investigated HLA alleles in autoimmune hepatitis (AIH) patients with or without anti-gAChR antibodies. Methodology/Principal Findings Genomic DNA from 260 patients with type-1 autoimmune hepatitis (AIH) were genotyped for HLA-A, B, DRB1, and DQB1 loci. Anti-gAChR antibodies in the sera form AIH patients were measured using the luciferase immunoprecipitation system, and examined allelic association in patients with or without anti-gAChR antibodies. Methodology/ Methods We detected anti-α3 or -β4 gAChR antibodies in 11.5% (30/260) of patients with AIH. Among AIH patients there was no significant association between HLA-A, B DQB1 alleles and the positivity for anti-gAChR antibodies. Whereas the HLA-DRB1*0403 allele showed a significantly increased frequency in AIH patients with anti-gAChR antibodies compared with those without anti-gAChR antibodies. Conclusions/Significance The frequency of the HLA-DRB1*0403 allele differed among Japanese patients with AIH according to the presence or absence of anti-gAChR antibodies. Our findings suggest that particular HLA class II molecules might control the development of anti-gAChR antibodies in the autoimmune response to gAChR.
-
Association between Anti-Ganglionic Nicotinic Acetylcholine Receptor (gAChR) Antibodies and HLA-DRB1 Alleles in the Japanese Population.
Public Library of Science (PLoS), 1Co-Authors: Yasuhiro Maeda, Osamu Higuchi, Akihiro Mukaino, Kiyoshi Migita, Hiroshi Furukawa, Atsumasa Komori, Minoru Nakamura, Satoru Hashimoto, Shinya Nagaoka, Seigo AbiruAbstract:Anti-ganglionic nicotinic acetylcholine receptor (gAChR) antibodies are observed in autoimmune diseases, as well as in patients with autoimmune autonomic ganglionopathy. However, the genetic background of anti-gAChR antibodies is unclear. Here, we investigated HLA alleles in autoimmune hepatitis (AIH) patients with or without anti-gAChR antibodies.Genomic DNA from 260 patients with type-1 autoimmune hepatitis (AIH) were genotyped for HLA-A, B, DRB1, and DQB1 loci. Anti-gAChR antibodies in the sera form AIH patients were measured using the luciferase immunoprecipitation system, and examined allelic association in patients with or without anti-gAChR antibodies.We detected anti-α3 or -β4 gAChR antibodies in 11.5% (30/260) of patients with AIH. Among AIH patients there was no significant association between HLA-A, B DQB1 alleles and the positivity for anti-gAChR antibodies. Whereas the HLA-DRB1*0403 allele showed a significantly increased frequency in AIH patients with anti-gAChR antibodies compared with those without anti-gAChR antibodies.The frequency of the HLA-DRB1*0403 allele differed among Japanese patients with AIH according to the presence or absence of anti-gAChR antibodies. Our findings suggest that particular HLA class II molecules might control the development of anti-gAChR antibodies in the autoimmune response to gAChR
Andri Rauch - One of the best experts on this subject based on the ideXlab platform.
-
prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the western australian hiv cohort study
Clinical Infectious Diseases, 2006Co-Authors: Andri Rauch, David Nolan, E Mckinnon, C. Almeida, A. Martin, Simon MallalAbstract:Abacavir therapy is associated with significant drug hypersensitivity in ∼8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allelle. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701–negative recipients.
-
prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the western australian hiv cohort study
Clinical Infectious Diseases, 2006Co-Authors: Andri Rauch, David Nolan, E Mckinnon, C. Almeida, A. Martin, Simon MallalAbstract:Abacavir therapy is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allele. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701-negative recipients.
Kiyotaka Kuzushima - One of the best experts on this subject based on the ideXlab platform.
-
the hla a 0201 restricted minor histocompatibility antigen ha 1h peptide can also be presented by another hla a2 subtype a 0206
Bone Marrow Transplantation, 2007Co-Authors: Hiroki Torikai, Yoshiki Akatsuka, H Miyauchi, Seitaro Terakura, M Onizuka, Kunio Tsujimura, K Miyamura, Yasuo Morishima, Yasuhiro Kodera, Kiyotaka KuzushimaAbstract:HA-1H is one of the most attractive minor histocompatibility antigens (mHA) as a target for immunotherapy of hematopoietic malignancies, but HLA-A*0201 and HLA-B60 molecules capable of presenting HA-1H-derived peptides are less common in eastern Asian populations when compared with Caucasian populations. Therefore, an attempt was made to search for novel epitopes presented by HLA alleles other than those previously reported by generating CTL lines from patients undergoing HLA-identical, HA-1 disparate hematopoietic stem cell transplantation (hematopoietic SCT) by stimulation with a 29-mer HA-1H peptide spanning a central polymorphic histidine (His). Two CTL clones established were found to be restricted by HLA-A*0206, which is the second or third most common HLA-A2 subtype worldwide. Epitope mapping revealed that the clones recognized the same nonameric peptide as A*0201-restricted HA-1H, VLHDDLLEA. This epitope was unexpected, since it does not contain any preferred anchor motifs for HLA-A*0206. However, an HLA peptide binding assay revealed stronger binding of this peptide to A*0206 than to A*0201. Interestingly, HLA-A*0206-restricted CTL clones could lyse both HLA-A*0206+ and HLA-A*0201+ targets (including leukemic blasts) that express HA-1H peptide endogenously, whereas an HLA-A*0201-restricted, HA-1H-specific CTL clone failed to lyse HLA-A*0206+ targets. This finding will expand the patient population who can benefit from HA-1H-based immunotherapy.
-
The HLA-A^*0201-restricted minor histocompatibility antigen HA-1^H peptide can also be presented by another HLA-A2 subtype, A^*0206
Bone Marrow Transplantation, 2007Co-Authors: Hiroki Torikai, Yoshiki Akatsuka, H Miyauchi, Seitaro Terakura, M Onizuka, Kunio Tsujimura, K Miyamura, Yasuo Morishima, Yasuhiro Kodera, Kiyotaka KuzushimaAbstract:HA-1^H is one of the most attractive minor histocompatibility antigens (mHA) as a target for immunotherapy of hematopoietic malignancies, but HLA-A^*0201 and HLA-B60 molecules capable of presenting HA-1^H-derived peptides are less common in eastern Asian populations when compared with Caucasian populations. Therefore, an attempt was made to search for novel epitopes presented by HLA alleles other than those previously reported by generating CTL lines from patients undergoing HLA-identical, HA-1 disparate hematopoietic stem cell transplantation (hematopoietic SCT) by stimulation with a 29-mer HA-1^H peptide spanning a central polymorphic histidine (His). Two CTL clones established were found to be restricted by HLA-A^*0206, which is the second or third most common HLA-A2 subtype worldwide. Epitope mapping revealed that the clones recognized the same nonameric peptide as A^*0201-restricted HA-1^H, VL H DDLLEA. This epitope was unexpected, since it does not contain any preferred anchor motifs for HLA-A^*0206. However, an HLA peptide binding assay revealed stronger binding of this peptide to A^*0206 than to A^*0201. Interestingly, HLA-A^*0206-restricted CTL clones could lyse both HLA-A^*0206^+ and HLA-A^*0201^+ targets (including leukemic blasts) that express HA-1^H peptide endogenously, whereas an HLA-A^*0201-restricted, HA-1^H-specific CTL clone failed to lyse HLA-A^*0206^+ targets. This finding will expand the patient population who can benefit from HA-1^H-based immunotherapy.